Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis.

Key Points

• This research aims to evaluate the effectiveness of molecular targeted therapy combined with chemotherapy for treating platinum-resistant ovarian cancer.
• Conducted a systematic review and network meta-analysis of existing clinical trials.
• Compared various treatment combinations involving bevacizumab and other agents.
• Emphasized efficacy and safety outcomes for different regimens.
• Bevacizumab-based combinations consistently show benefits for patients with platinum-resistant ovarian cancer.
• Paclitaxel + bevacizumab is identified as the best option for balancing effectiveness and safety.
• Topotecan + sorafenib is suggested as a viable alternative for patients who cannot receive anti-angiogenic therapy.